Physician profile
Robert Lee Ochs
NPI 1043288277
$11,464.89
in general payments reported to CMS, 2019-2025
28 companies · $2,238 in 2025
The $2,238 reported for 2025 was more than what 79% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,530 · 2020: $561 · 2021: $985 · 2022: $1,715 · 2023: $1,954 · 2024: $2,482 · 2025: $2,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,657 · Education: $16.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,657.16 |
| Education | $16.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,398.75 | 2019-2025 | |
| Lilly USA, LLC | $995.16 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Ucb, INC. | $810.67 | 2019-2025 | Bimzelx |
| Janssen Biotech, INC. | $810.66 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $773.11 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Genzyme Corporation | $645.49 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $616.52 | 2019-2025 | Cabtreo, Siliq, Jublia |
| E.R. Squibb & Sons, L.L.C. | $487.55 | 2022-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $477.71 | 2021-2025 | Tremfya |
| Pfizer INC. | $463.26 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $410.04 | 2021-2024 | Dupixent |
| Incyte Corporation | $319.63 | 2022-2025 | Opzelura |
| Dermavant Sciences, INC. | $313.93 | 2022-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $277.63 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $261.69 | 2023-2024 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $223.98 | 2019-2023 | Klisyri, Seysara |
| Amgen INC. | $209.54 | 2019-2025 | Otezla, Otezla |
| Organon LLC | $181.18 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $169.89 | 2019-2025 | |
| Dermira, INC. | $124.99 | 2019 | |
| Aclaris Therapeutics, INC. | $124.98 | 2019 | |
| Journey Medical Corporation | $102.54 | 2022 | |
| Sun Pharmaceutical Industries INC. | $95.06 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $78.85 | 2019-2020 | |
| Leo Pharma INC. | $47.71 | 2019-2023 | Adbry |
| Sebela Pharmaceuticals INC. | $15.60 | 2019 | |
| Revance Therapeutics, INC. | $15.00 | 2024 | Daxxify |
| Biofrontera INC. | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ochs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.